Generics, Supergenerics and Patent Strategies

Is production of generic medicines part of your core business? Or does generic competition present a challenge to your activities?

With many key blockbuster drugs coming off patent in the next few years, there’s never been a better time to understand the generics industry and market. SMi’s 11th annual Generics, Supergenerics and Patent Strategies conference is a great opportunity for those attempting to do just that. Key issues to be addressed at the conference will include:

• Why do markets like Ireland, Belgium and Spain have such low generic uptake in comparison to others such as Germany or the UK?
• Discover how generic competition affects pricing and reimbursement for both generic and innovative producers
• Future prospects for the EU and US generics market
• The latest IP developments
• The challenge of China and India – each country’s market, industrial potential and intellectual property and regulatory environment analysed in depth.

Confirmed speaker include:

• Zhijun Jiang, Vice President, Head of European Research and Development, Barr Laboratories
• Rahul Garella, Vice President, API Business, Glenmark Pharmaceuticals
• William Haddad, Chairman and CEO, Biogenerics
• Brian Tempest, Chief Mentor and Executive Vice Chairman - recently retired and now Non-Executive Director, Ranbaxy Laboratories
• Aleksandar Danilovski, Senior Director, Head of Global API R&D, Pliva Research and Development
• Milena Izmirlieva, Senior Analyst, Global Insight
• Albin J. Nelson, Partner, Schwegman, Lundberg, Woessner IP
• Nora Kareela, CEO, Ipsat Therapies
• Deborah Taylor, Market Development Manager, Colorcon
• Malcolm Ross, CEO, Generapharm
• Duncan Curley, Director, Innovate Legal
• Nawab Qizilbash, Director, Oxon Clinical Epidemiology
• Brian Lovatt, Managing Director and Cheif Executive, Vision Healthcare
• Henning Blume, CEO, SocraTec
• Paul Ranson, Parter, Fasken Martineau Stringer Saul LLC